Revance Therapeutics Inc

NASDAQ:RVNC   3:22:30 PM EDT
12.60
-0.23 (-1.79%)
Other Pre-Announcement

Revance Reports Third Quarter 2021 Financial Results, Provides Corporate Update

Published: 11/09/2021 22:09 GMT
Revance Therapeutics Inc (RVNC) - Revance Reports Third Quarter 2021 Financial Results, Provides Corporate Update.
Qtrly Total Revenue $19.7 Million Versus $3.8 Million.
Qtrly Basic and Diluted Net Loss per Share $1.10.
Revance Therapeutics - Due to Crl Received by Company From FDA, Withdrawing Previously Announced Cash Guidance.
Q3 Earnings per Share View $-1.15, Revenue View $20.3 Million -- Refinitiv Ibes Data (analyst estimates).